Replimune Group, Inc. (REPL) company profile
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
About Replimune
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a clinical-stage biotechnology firm that develops oncolytic immunotherapies designed to activate the immune system against cancer. Its proprietary RPx platform utilizes an engineered herpes simplex virus type 1 to selectively destroy tumor cells and stimulate systemic anti-tumor responses. The pipeline includes lead drug candidate RP1, evaluated for advanced melanoma, non-melanoma skin cancers, and skin cancers in organ transplant recipients, as well as RP2, which targets metastatic uveal melanoma and other solid tumors. These therapies serve adult cancer patients, particularly individuals with advanced or treatment-resistant malignancies.
The business operates an in-house manufacturing facility spanning approximately 63,000 square feet in Framingham, Massachusetts. Its geographic presence includes granted patents across several jurisdictions, including the United States, the European Union, Japan, China, Australia, Israel, and other international regions. The provided text does not identify the location of the company's corporate headquarters.
Summary of the business section of Replimune's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Replimune Group, Inc.
- Headquarters
- Woburn, MA
- Address
- 500 Unicorn Park 01801
- Phone
- (781) 222-9600
- Website
- replimune.com
- Employees
- 465, Mar 31, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- REPL
- Exchange
- Nasdaq
- IPO date
- Jul 23, 2018
- Shares outstanding
- 95M, Oct 23, 2026
- Public float
- $234.50M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1737953
- CUSIP
- 76029N106
- ISIN
- US76029N1063
- FIGI
- BBG00L8Z22R1
- Share class FIGI
- BBG00L8Z22S0
- LEI
- 549300AY704NEIRC4K64
- EIN
- 82-2082553
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sushil Patel | Chief Executive Officer, Director | 708,151 |
| Emily Luisa Hill | Chief Financial Officer | 215,852 |
| Andrew Schwendenman | Chief Accounting Officer | 99,425 |
| Konstantinos Xynos | Chief Medical Officer | 224,215 |
| Christopher Sarchi | Chief Commercial Officer | 180,962 |
| Joseph P. Slattery | Director | 1,467 |
| Kapil Dhingra | Director | 21,669 |
| Philip Astley-Sparke | Director | 1,362,414 |
| Julian Baker | Director | – |
| Bros. Advisors Lp Baker | Director | – |
| Bros. Advisors (GP) LLC Baker | Director | – |
| Brothers Life Sciences LP Baker | Director | – |
| Felix Baker | Director | 10,116,095 |
| 667, L.P. | Director | – |
| Paolo Pucci | Director | – |
| Madhavan Balachandran | Director | – |
| Dieter Weinand | Director | – |
| Christy J. Oliger | Director | – |
| Veleka Peeples-Dyer | Director | – |
| Michael Goller | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $5.85M | $3.62M | $2.10M | $43 | – |
| FY2025 | $3.70M | $4.88M | $1.61M | $55 | – |
| FY2024 | $6.02M | $1.15M | $2.92M | $46 | – |
| FY2023 | $3.65M | $3.73M | $2.60M | $104 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Sushil Patel Chief Executive Officer | $700.00K | $3.38M | $1.45M | $315.00K | $6.65K | $5.85M | +58% |
| Emily Hill Chief Financial Officer | $532.00K | $970.80K | $393.45K | $196.32K | – | $2.09M | +31% |
| Konstantinos Xynos Chief Medical Officer | $536.00K | $970.80K | $393.45K | $198.32K | $14.21K | $2.11M | +30% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 23, 2018
- Offer price
- $15.00
- Securities offered
- 6,700,000
- Gross proceeds
- $100.50M
- Exchange
- Nasdaq
- First trading day
- Jul 20, 2018
- First-day close
- $15.16+1.1%
- Lock-up ends (est.)
- Jan 16, 2019
“The initial public offering price is $15.00 per share of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we employed 465 employees, all of which are full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 23, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 17, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?